62 related articles for article (PubMed ID: 25218128)
1. Reply: To PMID 24949545.
Bendifallah S; Darai E
Am J Obstet Gynecol; 2015 Jan; 212(1):116-7. PubMed ID: 25218128
[No Abstract] [Full Text] [Related]
2. Statistical flaws in the development of a prediction model.
Collins GS
Am J Obstet Gynecol; 2015 Jan; 212(1):116. PubMed ID: 25218126
[No Abstract] [Full Text] [Related]
3. Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors.
Bendifallah S; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
Am J Obstet Gynecol; 2014 Dec; 211(6):637.e1-6. PubMed ID: 24949545
[TBL] [Abstract][Full Text] [Related]
4. Minimal invasive approaches for large ovarian cysts: a careful choice.
Bellati F; Gasparri ML; Ruscito I; Caccetta J; Benedetti Panici P
Arch Gynecol Obstet; 2013 Mar; 287(3):615-6. PubMed ID: 22987258
[No Abstract] [Full Text] [Related]
5. [Precursors of ovarian carcinoma and epithelial borderline tumors: current topics in pathology].
Kiyokawa T
Nihon Rinsho; 2012 Jun; 70 Suppl 4():517-22. PubMed ID: 23156301
[No Abstract] [Full Text] [Related]
6. Trismus and diffuse polymyalgia: an unusual presentation of recurrent metastatic ovarian cancer.
Benjamin R; Zhai J; Morgan R; Prakash N
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24835804
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
8. Mediastinal recurrence from ovarian cystadenocarcinoma presenting as pleuro-pericardial cyst.
Lococo F; Charpentier MC; Guinet C; Brandolini J; Alifano M; Regnard JF
Eur Rev Med Pharmacol Sci; 2014; 18(15):2094-6. PubMed ID: 25070811
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma).
Koskas M; Uzan C; Gouy S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Ann Surg Oncol; 2011 Jan; 18(1):40-8. PubMed ID: 20737216
[TBL] [Abstract][Full Text] [Related]
10. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
11. Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases.
Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Siriaunkgul S
Int J Gynecol Pathol; 2014 Mar; 33(2):176-85. PubMed ID: 24487473
[TBL] [Abstract][Full Text] [Related]
12. Reply: To PMID 23583217.
Erickson BK; Landen CN; Conner MG
Am J Obstet Gynecol; 2013 Oct; 209(4):396. PubMed ID: 23665249
[No Abstract] [Full Text] [Related]
13. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Benedetti Panici P; De Vivo A; Bellati F; Manci N; Perniola G; Basile S; Muzii L; Angioli R
Ann Surg Oncol; 2007 Mar; 14(3):1136-42. PubMed ID: 17195909
[TBL] [Abstract][Full Text] [Related]
14. Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study.
Snir OL; Buza N; Hui P
Histopathology; 2016 Sep; 69(3):383-92. PubMed ID: 26952875
[TBL] [Abstract][Full Text] [Related]
15. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
[TBL] [Abstract][Full Text] [Related]
16. Corpora albicantia-like bodies in extraovarian lesions.
Michal M; Hes O
Int J Surg Pathol; 2004 Jul; 12(3):298. PubMed ID: 15306946
[No Abstract] [Full Text] [Related]
17. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathology of ovarian cancer.
Sanseverino F; D'Andrilli G; Petraglia F; Giordano A
Anal Quant Cytol Histol; 2005 Jun; 27(3):121-4. PubMed ID: 16121632
[TBL] [Abstract][Full Text] [Related]
20. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
